201 9 Annual Status Update on Measles and Rubella Elimination (COUNTRY NAME HERE) Dear NVC and national technical counterparts, dear colleagues, We kindly ask you to follow the definitions (please see Annex 1 .1 ) and instructions provided in th is form , and to enter numbers or text as required in each particular segment (table, text box , other). If you are using your own definitions and indicators, please provide an explanation and clarification why and how these could be considered equivalent to or as an adequate replacement for the WHO definitions and indicators. If the NVC would like to provide additional data and information to the RVC, please submit them as separate document(s). This update is to be submitted to the WHO Regional Office for Europe by 15 April 20 20 . Please upload an electronic version of the form and a scanned copy of the table with sign atures of all the NVC members to the RVC SharePoint: http://workspace.who.int/sites/EURORVC How to upload the report: Make a copy of your report and any supporting documents and supplementary data in original (Microsoft Word , Excel, etc. ) format. PLEASE DO NOT CONVERT THIS FILE INTO PDF FORMAT! Login to RVC SharePoint, at “ http://workspace.who.int/sites/EURORVC “ , using the password provided by the WHO Secretariat to the NVC chairperson and EPI manager. Once you are in the RVC SharePoint Click on “Country Annual Status Reports”. Select and click on your country folder. Open the folder for year of reporting (201 9 ). D rag each file to the folder (specified area on top of your folder’s page) and it will be copied. Double - check that the files are uploaded under the Country Annual Status Reports/Your country name – close and re-open your folder, and if names of uploaded files are not visible repeat procedure. Should you have any problems with access to the RVC SharePoint or in uploading the report, please contact the WHO Secretariat by e-mail (
[email protected] ). The National Verification Committee (NVC) conclusion on measles and rubella elimination status in 201 9 Please provide your statement on the status of measles and rubella viruses’ circulation in your country, based on the information provided by the national surveillance and immunization systems. Tick one of the boxes below as deemed appropriate and provide rationale (main facts that led to the NVC’s conclusion) in the text box below. If you have difficulties in deciding which one of the three status definitions for measles and rubella elimination applies , please leave the boxes unchecked and explain in the text box. Measles Endemic FORMCHECKBOX Interrupted endemic transmission FORMCHECKBOX Re-established endemic transmission FORMCHECKBOX The NVC conclusion is based on the following : ( please see the guiding text below , then delete and replace it with your text addressing the mentioned areas ) Epidemiology of measles in 201 9 – number and description of cases and outbreaks (person-time-place, seasonality, immunization status, known origin, rate of confirmation and discarding of cases) . Even it is not directly related to verification, you may include information about measles mortality and cases of subacute sclerosing panencephalitis (SSPE). Measles surveillance quality in 201 9 – systems quality and capacity to detect, report, investigate and confirm/discard suspected cases all over the country for the entire year, performance against surveillance indicators, other reliable indicators used in country to confirm adequate surveillance quality and performance, additional activities (active case finding, retrospective case/data analysis, addressing “silent” territories and populations), integration with laboratory segment of surveillance for confirming cases and genotypes/lineages (sporadic cases and outbreaks) . Molecular epidemiology of measles in 201 9 – comprehensive analysis of epidemiological and laboratory data on detected genotypes/lineages of measles viruses, and extended to analysis of available data from the previous and following year looking for/to exclude continuous circulation of >12 month s. Activities to increase population immunity in 201 9 – routine immunization programme coverage at national and subnational level, and especially where suboptimal programme performance exists (e.g. age cohorts, territories and/or specific population with known low coverage), supplemental immunization activities and coverage, additional studies and surveys about immunity to measles and rubella ( MR ) . Sustainability of and commitment to activities on MR elimination in 201 9 – political commitment of decision - making structures and main players, involvement of partners, promotion of and advocacy for elimination, sustainability of immunization programme, political and technical regulation s and guidelines developed or renewed, secur ity of funds and vaccine supply, organized activities aimed at particular groups (e.g. health care workers to increase knowledge or general population to increase demand ) . Characteristics and quality of data for 201 9 – Are the data complete, available, valid, representative, consistent ? Are any additional data from other sources used to validate existing data and ensure adequate understanding of measles epidemiology and asses sment of elimination status ? Rubella Endemic FORMCHECKBOX Interrupted endemic transmission FORMCHECKBOX Re-established endemic transmission FORMCHECKBOX The NVC conclusion is based on the following: (please see the guiding text below, then delete and replace it with your text addressing the mentioned areas) Epidemiology of rubella and CRS in 201 9 – number and description of cases and outbreaks (person-time-place, seasonality, immunization status, known origin, rate of co nfirmation and discarding of cases) . Rubella and CRS surveillance quality in 201 9 – systems quality and capacity to detect, report, investigate and confirm/discard suspected cases all over the country for the entire year, performance against surveillance indicators, other reliable indicators used in country to confirm adequate surveillance quality and performance, additional activities (active case finding, retrospective case/data analysis, addressing “silent” territories and populations), integration with laboratory segment of surveillance for confirming cases and genotypes/lineages (sporadic cases and outbreaks) . Molecular epidemiology of rubella in 201 9 – comprehensive analysis of epidemiological and laboratory data on detected genotypes/lineages of measles viruses, and extended to analysis of available data from previous and following year s looking for/to exclude continuous circulation of >12 month s . Activities to increase population immunity in 201 9 – routine immunization programme coverage at national and subnational level, and especially where suboptimal programme performance exists (e.g. age cohorts, territories and/or specific population with known low coverage), supplemental immunization activities and coverage, additional studies and surveys about immunity to MR . Sustainability of and commitment to activities on MR elimination in 201 9 – political commitment of decision - making structures and main players, involvement of partners, promotion of and advocacy for elimination, sustainability of immunization programme, political and technical regulation s and guidelines developed or renewed, secur ity of funds and vaccine supply, organized activities aimed at particular groups (e.g. health care workers to increase knowledge or general population to increase demand) . Characteristics and quality of data for 201 9 – Are data complete, available, valid, representative, con si stent ? Are any add itional data from other sources used to validate existing data and ensure adequate understanding of rubella (with CRS) epidemiology and assess ment of elimination status ? These conclusions are approved by the National Verification Committee (NVC) Name NVC status Position Organization Contact details (email, tel.) Signature 1 Chairperson 2 Secretariat person* 3 Member 4 Member 5 Member 6 Member *Person with administrative duties, who may also be responsible for documenting, maintaining records and overseeing logistics. This person may be from the national immunization or surveillance programme. The RVC sent you its conclusions and recommendations from 7 th RVC meeting . In the text box below please provide the NVC and national technical counterparts’ response to any RVC request for additional information or clarification. Text box Sections of the ASU form Please complete s ections 1- 3 , and us/ add forms from Section 4 as needed , to repor t outbreaks and supplemental immunization activities ( SIA ) . Please use provided Excel file to help you analyse the data and complet e the ASU, and then upload/send the Excel file to the RVC/Secretariat along with the ASU form . Additional information to help you analyse the data and complete the forms is provided in Annex 1. Section 1: Country measles and rubella profile for 201 9 1.1 Epidemiologic analysis of measles, rubella and CRS 1.2 Laboratory performance - national framework for MR laboratory testing 1.3 Performance of measles and rubella surveillance against indicators 1.4 Population immunity to measles and rubella Section 2: Update of general programme activities by components Section 3: Activities of the National Verification Committee (NVC) and its Secretariat 3.1 Activities of the NVC in the year under review 3.2 The NVC Secretariat (list of national staff involved in preparation of ASU) Section 4 : Additional data on measles, rubella and CRS in 201 9 4.1 Maps and epi curves with distribution of suspected and confirmed measles and rubella cases and measles and rubella outbreaks in 201 9 4.2 Form for outbreak reporting (use one form per each of the detected outbreaks) 4.3 Form for technical report on SIA Annex 1 : WHO guiding documents and examples 1 .1 Definitions 1 .2 Description of “Indicators and targets” for measuring performance of measles and rubella surveillance 1 . 3 Sustain measles and rubella elimination after verification - Discussion points on risk for re-establishing endemic transmission of diseases Abbreviations ASU Annual Status Update (form) CRS congenital rubella syndrome EQA external quality assurance MCV measles-containing vaccine MeaNS WHO Measles Nucleotide Surveillance online database (www.who-measles.org) NVC National Verification Committee RCV rubella-containing vaccine RubeNS WHO Rubella Nucleotide Surveillance online database (www.who-rubella.org) RVC Regional Verification Commission SIA Supplemental immunization activities Section 1: Country measles and rubella profile for 201 9 Epidemiologic analysis of measles, rubella and CRS Progress towards measles and rubella elimination , 201 7 - 201 9 - Incidence of measles and rubella and total number of CRS cases in last three years 575945 8387715 0 0 Incidence or n umber of cases 201 7 201 8 201 9 Remarks Measles incidence per 1 million population Rubella incidence per 1 million population Number of CRS cases Country population – number (denominator) used to calculate incidence in table above : FORMTEXT The numerator is the total number of measles/rubella cases including laboratory-confirmed, epidemiologically linked and clinically compatible cases but excluding imported cases . For CRS cases please provide total number of cases classified as CRS , excluding imported cases . Epidemiology of measles, rubella and CRS in 201 9 Measles and rubella surveillance is organized as: FORMCHECKBOX Disease-specific surveillance (measles surveillance, rubella surveillance) FORMCHECKBOX Rash and fever surveillance (syndrome-based) FORMCHECKBOX Both types of surveillance systems are in place FORMCHECKBOX Other (please describe in text box below) Text box Are specimens from ALL suspected cases routinely tested for both diseases by a laboratory ? FORMCHECKBOX No FORMCHECKBOX Yes, for both diseases, in parallel or in sequence (if testing for one disease is negative) FORMCHECKBOX Yes, but partially/for some of cases (if there are national guidelines or proposed testing algorithm – please explain): Text box Number of measles and rubella cases in 201 9 Total number of suspected cases (from diseases-specific and syndrome-based surveillance) Total number of cases classified as measles or rubella (laboratory-confirmed, epidemiologically linked and clinically compatible cases) Number of d iscarded cases (please indicate if these are discarded for both diseases) Measles Rubella Value in cell “Total number of suspected cases” should be equal to the sum of values presented in “ Total number of cases c lassified as measles or rubella ” and “ Total number of d iscarded cases ” . I nclude laboratory-confirmed, epidemiologically linked and clinically compatible cases , regardless of origin (include imported) . If suspected cases are systematically investigated/tested for both diseases in your surveillance system (syndromic-based surveillance ; simultaneous or sequential testing in laboratories), cases suspected for measles may be included in the total number of cases suspected for rubella, and conversely - cases suspected for rubella may be included as cases suspected for measles. Number of measles cases, by case classification and origin of infection Measles Laboratory-confirmed (A) Epidemiologically linked (B) Clinically compatible (C) Total (A+B+C) Imported (I) Import-related (II) Endemic (III) Unknown origin (IV) Total (excluding imported cases) (II + III + IV) Note: Please use the E xcel spreadsheet provided with this ASU, as it can help you in completing this table Number of rubella cases, by case classification and origin of infection Rubella Laboratory-confirmed (A) Epidemiologically linked (B) Clinically compatible (C) Total (A+B+C) Imported (I) Import-related (II) Endemic (III) Unknown origin (IV) Total (excluding imported cases) (II + III + IV) Note: Please use the Excel spreadsheet provided with this ASU, as it can help you in completing this table Number of CRS cases, by case classification and origin of infection CRS Laboratory-confirmed (A) Epidemiologically linked (B) Clinically compatible (C) Total (A+B+C) Imported (I) Import-related (II) Endemic (III) Unknown origin (IV) Total (excluding imported cases) (II+III+IV) Note: Please use the Excel spreadsheet provided with this ASU, as it can help you in completing this table Age and vaccination status of laboratory-confirmed, epidemiologically linked or clinically compatible cases of measles and rubella (excluding imported cases) Age and vaccination status of measles cases (excluding imported cases ) Measles < 1 year 1-4 years 5-9 years 10-14 years 15-19 years 20-29 years 30 Unknown age Total 0 doses 1 dose 2 or more doses Unknown status Total Age and vaccination status of rubella cases (excluding imported cases) Rubella < 1 year 1-4 years 5-9 years 10-14 years 15-19 years 20-29 years 30 Unknown age Total 0 doses 1 dose 2 or more doses Unknown status Total List of administrative territories with measles and rubella cases a) Total n umber of confirmed measles cases by month (classified as laboratory-confirmed, epidemiologically-linked or clinically compatible), regardless of origin (includ ing imported) Administrative territory and its population size Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Total Add as many rows as you may need for territories– one and the same type/ level of administrative organization (district, region, municipality) that provides routine diseases surveillance data in your system. b) Total n umber of confirmed rubella cases (classified as laboratory-confirmed, epidemiologically linked or clinically compatible), regardless of origin (includ ing imported) Administrative territory and its population size Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Total Add as many rows as you may need for territories– one and the same type/ level of administrative organization (district, region, municipality) that provides routine diseases surveillance data in your system. Outbreaks in 2019 and molecular epidemiology NOTE : If genotyping data are available, p lease note that each outbreak or chain of transmission should have only one genotype -variant . If more than one genotype -variant is reported for an outbreak, this refers to more than one outbreak/ chain of transmission and should be described as two separate outbreak s/ chain s of transmission in the table. Countries with comprehensive data are encouraged to use the additional Excel sheets provided as tool for better visuali z ation . Please provide definition for an outbreak of measles and rubella used in your country in the text box below : Text box 1.1.4.1 Measles Measles outbreaks and sporadic cases in 201 9 by availability of the genotype information MEASLES Genotyped Not genotyped Total Number of outbreaks/chains of transmission Number of cases that are part of outbreaks/chains of transmission Number of sporadic cases that are not part of outbreaks/ chains of transmission Total number of cases The v alue in the cell highlighted in orange should be the total number of cases classified as measles and the same as the value for the Total number of cases classified as measles in table 1.1.1.c Measles outbreaks in 201 9 (list ALL outbreaks ; i f your country only reported sporadic measles cases and NO outbreaks, please go directly to table d ) Outbreak ID Name of the affected territory (national, or list of affected sub-national territories ) Duration (Date of onset of the first case , date of onset of the last case; or “ongoing” ) Total num ber of cases in outbreak in 201 9 First case by origin (Imported or not-imported) Outbreak genotyped ( y es/ n o) Outbreak report form attached to the ASU (Yes/No) Add as many rows a s you need Genotyped measles outbreaks/chain s of transmission Genotype-variant ( MeaNS distinct sequence ID) Outbreaks (list all ID s ) Name of the affected territory (national, or list of affected subnational territories ) Total number of cases in 2019 Duration (Date of onset of the first case and date of onset of the last case; or “ongoing” ) Documented importation for first case (yes/no) Are there sporadic cases with the same variant that are not part of the identified outbreak/ chain of transmission? If yes, how many cases ? Please give date of first and last of these sporadic case s SUM - Total number of genotyped outbreaks/chains of transmission SUM- Total number of cases in outbreak s /chain s of transmission SUM - Total number of sporadic cases with genotype Add as many rows as you need, or remove not used rows (e.g. only one genotype-variant detected) Measles sporadic cases with different genotype-variant(s) than those reported in table c) Please fill in this table ONLY IF 1) there were NO genotyped outbreaks at all reported in 201 9 or 2) if NO outbreaks ha d the same genotype-variant(s). Otherwise, please include the sporadic cases above in the last column of table c). Genotype-variant ( MeaNS distinct sequence ID) Case ID / EpidNo Name of subnational territory from w he re it was reported Date of onset Documented importation (yes/no) SUM (Total number of cases ) Add as many rows as you need, or remove not used rows (e.g. only one genotype-variant detected) 1.1.4.2 Rubella Rubella outbreaks and sporadic cases in 201 9 by availability of the genotype information RUBELLA Genotyped Not genotyped Total Number of outbreaks/chains of transmission Number of cases that are part of outbreaks/chains of transmission Number of sporadic cases that are not part of outbreaks/chains of transmission Total number of cases The v alue of the cell highlighted in orange should be the total number of cases classified as rubella and the same as the value for the Total number of cases classified as rubella in table 1.1.1.c Rubella outbreaks in 201 9 (list ALL outbreaks; i f your country only reported sporadic rubella cases and NO outbreaks, please go directly to table d ) Outbreak ID Name of the affected territory (national, or list of affected sub-national territories ) Duration (Date of onset of the first case and date of onset of the last case; or “ongoing”) Total number of cases in outbreak in 201 9 First case by origin (Imported or not-imported) Outbreak genotyped ( y es/ n o) Outbreak report form attached to the ASU ( y es/ n o) Add as many rows as you need Genotyped rubella outbreaks Genotype- RubeNS sample ID Outbreaks (list all ID s ) Name of the affected territory (national, or list of affected subnational territories) Total number of cases in 201 9 Duration (Date of onset of the first case and date of onset of the last case; or “ongoing”) Documented importation for first case (yes/no) Are there sporadic cases with the same variant that are not part of the identified outbreak/ chain of transmission? If yes, how many cases ? Please give date of first and last of these sporadic cases SUM - Total number of genotyped outbreaks/chains of transmission SUM- Total number of cases in outbreak s/chains of transmission SUM - Total number of sporadic cases with genotype Add as many rows as you need, or remove not used rows (e.g. only one genotype-variant detected) Rubella sporadic cases with different genotype- RubeNS sample ID than those reported in table c). Please fill in this table ONLY IF 1) there were NO genotyped outbreaks at all reported in 201 9 or 2) if NO outbreaks ha d the same genotype-variant(s). Otherwise, please include the sporadic cases above in the last column of table c). Genotype - RubeNS sample ID Case ID/ EpidNo Name of subnational territory from w he re it was reported Date of onset Documented importation (yes/no) SUM (Total number of cases Add as many rows as you need, or remove not used rows (e.g. only one genotype-variant detected) The RVC has noted that the collection and submission of more detailed subnational data (graphs and maps) would facilitate the verification process . Therefore, if available (especially if already included in the routinely collected and analy s ed data) and feasible, please provide outbreak maps (i.e. maps showing the distribution of confirmed measles and rubella cases recognized as constituting one outbreak or one chain of transmission) in Section 4.1 of the Annual Status Update 201 9 . Please insert them in the form, or upload them as supplementary documents. The RVC is asking the NVC and its secretariat to use Section 4.2 ( Outbreak reporting form ) to provid e outbreak data. It would be highly appreciated and useful if each imported case that was an “index” case for an outbreak explained in detail , by giving the name of the country where the index case was exposed and including available information on the place(s) or administrative district(s) within your country where exposure might have occurred. If this information cannot fit into the relevant cell of the form, it may be added in the textual description. As a reminder, imported measles cases are cases exposed outside the country during the 7 to 18 days prior to rash onset as supported by epidemiological and/or virologic al evidence, and not those who were exposed and infected due to contact with a person in or from another administrative territory in your country. Laboratory performance - national framework for measles and rubella laboratory testing in 201 9 Standard laboratory procedures for testing and case confirmation Please select ONE of the following: FORMCHECKBOX IgM serology is the first line of laboratory investigation; case confirmation may rely on additional tests if needed. FORMCHECKBOX Molecular detection is the first line of laboratory investigation; serology may be additionally performed or not. FORMCHECKBOX Other case confirmation procedure, please specify: FORMTEXT Testing and confirmation of cases by laboratory proficiency Select all that apply regarding testing of measles, ru bella and CRS suspected cases (more than one may apply) FORMCHECKBOX Testing conducted by WHO-accredited measles–rubella reference laboratory/ laboratories . FORMCHECKBOX Testing conducted by l aboratories having an established quality assurance programme with oversight by a WHO-accredited laboratory. FORMCHECKBOX Testing conducted by l aboratories having an established quality assurance programme and accredited by a national body/institution. Please specify EQA programme FORMTEXT FORMTEXT FORMTEXT FORMTEXT FORMTEXT FORMTEXT FORMTEXT FORMTEXT FORMTEXT FORMTEXT Name of national accrediting body FORMTEXT FORMTEXT FORMTEXT FORMTEXT FORMTEXT FORMTEXT FORMTEXT FORMTEXT Accreditation standard(s) FORMTEXT FORMTEXT FORMTEXT FORMTEXT FORMTEXT FORMTEXT FORMTEXT FORMTEXT FORMTEXT FORMCHECKBOX Other (p lease comment/describe ) FORMTEXT FORMTEXT FORMTEXT FORMTEXT FORMTEXT FORMTEXT FORMTEXT FORMTEXT FORMTEXT FORMTEXT Number o f suspected cases tested in 201 9 by type of the laboratory Systematic screening studies as well as any other results of general screenings of population should not be reported in this form ( e.g. survey for rubella in pregnancy) . Laboratory performing the test Number of suspected cases tested for measles Number of suspected cases tested for rubella Number of suspected cases tested for CRS WHO-accredited lab(s) Proficient labs overseen by WHO - accredited lab Nationally accredited labs Other labs Total Performance of measles and rubella surveillance against indicators Please u se th e Excel spreadsheet provided with this ASU 201 9 to calculate rates or percentage s required as surveillance indicators, and insert the calculated values in the tables of this section . Please add any comment s or clarification s in the “Remarks” column. Measles surveillance performance indicators a. Standard indicators Indicator Value for indicator Numerator Denominator Remarks Timeliness of reporting (to national level) (in %) Completeness of reporting (to national level) (in %) Rate of laboratory investigations (in %) Rate of discarded cases Representativeness of reporting discarded cases (in %) Viral detection (in %) Origin of infection identified (in %) Timeliness of investigation (in %) b. Alternative indicators – If the above standard indicators could be calculated using the available data, there is no need to provide alternative indicators . If data is not available to calculate the standard indicators, NVC should use these alternative indicators to assess the performance of measles surveillance. Indicator Value for indicator Numerator Denominator Remarks Timeliness of notification (in %; alternative to Timeliness and Completeness indicator) Rate of cases tested negative for measles IgM (alternative to Rate of Discarded Cases indicator) Rubella surveillance performance indicators a. Standard indicators Indicator Value for indicator Numerator Denominator Remarks Timeliness of reporting (to national level) (in %) Completeness of reporting (to national level) (in %) Rate of laboratory investigations (in %) Rate of discarded cases Representativeness of reporting discarded cases (in %) Viral detection (in %) Origin of infection identified (in %) Timeliness of investigation (in %) b. Alternative indicators – If the above standard indicators could be calculated using the available data, there is no need to provide alternative indicators . If data is not available to calculate the standard indicators, NVC should use these alternative indicators to assess the performance of measles surveillance. Indicator Value for indicator Numerator Denominator Remarks Timeliness of notification (in %; alternative to Timeliness and Completeness indicator) Rate of cases tested negative for rubella IgM (alternative to Rate of Discarded Cases indicator) Population immunity to measles and rubella Routine vaccination coverage of measles - and rubella - containing vaccines a. Summa ry of vaccination coverage, 201 7 - 201 9 Routine vaccination coverage 1 201 7 201 8 201 9 Remarks Measles-containing vaccine, 1st dose Measles-containing vaccine, 2nd dose Rubella-containing vaccine, 1st dose Rubella-containing vaccine, 2nd dose 1 Vaccination coverage as in the official national routine immunization reports (JRF) . b . Methods used to determine the immunization coverage Please describe the methods by which routine immunization coverage is determined, including both numerator and denominator data. Please clearly indicate the source of population statistics. 1st dose Description Source of data Comments Numerator Denominator 2nd dose Description Source of data Comments Numerator Denominator Example : Numerator : Number of children < 24 months of age that have received one dose of measles - and rubella - containing vaccine given after 12 months of age Denominator : N umber of children 12-23 months of age Source of data: A dministrative reports from subnational level (annually updated) Additional data to determine the population immunity in 201 9 Note: Additional data from rapid coverage monitoring, coverage surveys or seroprevalence studies, when available, should be included in the report. For published studies or final written reports, references may be appended to this report. Serological (S) or coverage (C) studies/surveys Targeted territory or subpopulation Results 1 2 3 Add /remove rows as needed Information of administrative territories with m easles/ r ubella-containing vaccine routine coverage 90% in 201 9 Are there any administrative territories with less than 90% coverage for either first and/or second dose of m easles and/or r u bella-containing vaccine in 201 9 ? (Please check the appropriate box) FORMCHECKBOX N o FORMCHECKBOX Y es (Please provide list of such territories in table below) FORMCHECKBOX Subnational coverage data are not collected or available FORMCHECKBOX No subnational administrative levels in the country Please list all administrative territories (for subnational level which immunization coverage data is collected/ available) where the coverage with the first and/or second dose was 90%. Total number of subnational te rritories in the country in 201 9 : FORMTEXT Territories with coverage less than 90% Population size Coverage 1 st dose (%) Coverage 2nd dose (%) 1. 2. 3. 4. 5. Add /remove rows as you need Information about h igh - risk population groups in the country Please indicate population groups with a higher than expected risk of developing/transmitting measles and/ or rubella due to insufficient level of vaccination coverage or known/possible measles or rubella transmission in the country of origin. Consider for example population groups for which vaccination coverage is influenced by religious beliefs or ethnic ity , residen ce in specific geographic or administrative areas, refugee or migrant status etc . Include high - risk groups here even though supplementary activities may have been implemented to improve coverage in these groups – these activities should be reported in the text box under 1.4.5 c. Q ualitative assessment of SIA . If details about these populations are not available, please note in the last column (Remarks) that your country is aware of the presence of these population groups. FORMCHECKBOX No high - risk population groups Description of high - risk population groups (please specify here) Estimated population size Estimated % of total population Estimated MR vaccination coverage Remarks Add /remove rows as you need Information on additional immunization activities in 201 9 Actions taken to improve the level of immunization coverage in selected territories and/or in high - risk population groups in 201 9 Supplemental immunization activities (SIA) Were supplementary immunization activities with measles/rubella – containing vac cine conducted in 201 9 (please check the appropriate box)? FORMCHECKBOX YES FORMCHECKBOX NO If supplementary immunization activities were conducted , please summarize results in the table below and complete the SIA Technical Report form ( Section 4.3, one for each of SIA) SIA conducted as national or subnational Type of SIA (e.g. catch-up, mop-up, follow-up) Vaccine used (M, MR, MMR) Dates (start-end) Age range of target group Target population size Coverage achieved (%) Independent monitoring of SIAs is an objective measure of SIA quality. The SIA guidelines developed for injectable vaccines (using measles - and rubella -containing vaccines) can be used as a reference. These are available at http://www.who.int/immunization/diseases/measles/SIA-Field-Guide.pdf?ua=1,&ua=1 Qualitative assessment of SIA According to administrative coverage and monitoring results (if done), provide qualitative assessment of SIA that was conducted. Indicate whether there were any geographic clusters and/or high - risk groups where SIA coverage was less than 90%. Section 2: Update of activities in country towards measles and rubella elimination Please indicate in the table below any programmatic changes related to measles, rubella and CRS that took place in your country in 201 9 . Please describe ongoing or new activities in the country in regards to CRS surveillance. Area of work Strategies ( considering national and WHO r egional strategies; any changes or new strategies introduced) I mmunization requirements and schedule, routine and supplemental Surveillance and reporting CRS - specific activities (ongoing and new) Other Section 3: Activities of the National Verification Committee (NVC) and its Secretariat Activities of the NVC in the year under review Please provide a brief summary of the NVC activities conducted in th e year under review ( you may extend your answer to include conducted and planned activities in the current year ) . I nclud e key issues addressed , and list any concerns that have arisen (e.g. NVC concerns about the national programme, challenges in organizing and/or holding regular NVC meetings ) Activity Date (Month/Year) Highlights Challenges 1 2 3 Add /remove rows as you need The NVC Secretariat (list of national staff involved in preparation of ASU) Name Function in national health system* Position Organization Contact details (e-mail, tel . ) 1 2 3 4 5 * Key national public health experts who are responsible for or involved in operational aspects of immunization programme, surveillance, measles/rubella reference laboratory and other programme areas. Section 4 : Additional data on measles, rubella and CRS in 201 9 Maps and epi curves with distribution of suspected and confirmed measles and rubella cases and measles and rubella outbreaks in 201 9 The RVC has noted that the collection and submission of more detailed subnational data (graphs and maps , epi curves with suspected/confirmed cases, epi curves with different genotypes ) would facilitate the verification process. Therefore, if available (especially if already included in the routinely collected and analy s ed data) and feasible, please provide : a) maps with distribution of confirmed and suspected measles and rubella cases by subnational administrative territories, preferably at the level of districts or equivalent basic administrative level (or a ny other territorial presentation of data) ; b) e pi curves with distribution of cases ( time / place ) . If it is technically challenging to insert them into this form, please upload/send them as supplementary documents. Outbreak reporting form (please fill-out one per each outbreak and add to ASU) Instructions to fill in the Measles/Rubella Aggregate Outbreak Reporting Form for reporting measles or rubella outbreaks to the WHO Regional Office for Europe Please send the outbreak reports to the WHO Regional Office Europe or ECDC , to the same address you send the monthly measles or rubella reports. Please submit this form for each measles or rubella outbreak in your country. This form should be sent as soon as an outbreak is reported by the referent national surveillance health institution (the one in charge for outbreak response). A final report should be submitted when the outbreak is finished (following national regulation and epidemiology of disease) and should capture the most accurate and updated data. Additional updates can be sent by the country , however a minimum of two reports per outbreak should be sent. Description of the cells in the reporting form: Outbreak Identification - 11 information cells Outbreak ID: Outbreak ID is used to identify, trace, match and update outbreak information. The ideal outbreak ID is MEA-CCC-YYYY-99. (CCC is the 3 character ISO3 code for the country, YYYY is year of outbreak and 99 is a series start ing from 01 to number the outbreaks sequentially) Country: Enter the name of the country. 1st and 2nd admin level: Specify the location of the outbreak's onset. Enter the name of the first and second administrative level in the country, according to territorial organization (e.g., 1st level region, 2nd district; 1st level province, 2nd municipalities; 1st level oblast, 2nd rayon.) Date of rash onset of first case: Indicate the date of rash onset for the index case. Date of rash onset of last case - Indicate the date of rash onset for the last case notified in the outbreak. [NOTE: This information should be indicated only in the final outbreak report.] Outbreak Notification Date - Indicate the date when the outbreak was notified to the referent surveillance health institution (e.g., reported by MD or health care institution) Considering differences between the surveillance and health systems in Member States, this date should be the actual date when the planning and performing of outbreak control measures started in the referent institution. Current Outbreak Status - Indicate "Ongoing" or "Finished". Outbreak end date - Indicate the date when the outbreak finished. Considering differences between the surveillance and health systems in the Member States, as well as different health regulations, the suggestion is to use date of the last case notification as the outbreak end date (if in the period of one maximal incubation for the outbreak - causing disease there are no other notified cases ) . [NOTE: This information should be indicated in the final outbreak report.] Importation (Y/N) - Indicate with "Yes" or "No" whether the outbreak is imported from another country. Measles imported case are cases exposed outside the country during the 7 to 18 days prior to rash onset as supported by epidemiological and/or virological evidence. If the index case came from or was exposed and infected due to contact with a person from another administrative territory in the country that is NOT an importation. In the following cell of the form enter the name of the country where the index case was exposed. Cases detail - 6 information cells No. of suspected cases (3 cells; Male, Female and Total) - indicate the number of suspected cases of measles or rubella by gender and as a total. A suspected case is any person who is under epidemiological, clinical and/or laboratory investigation during the outbreak; and who has clinical symptoms meeting the case definition for measles or rubella and/or possible epidemiological link with other suspected/confirmed case. No. Deaths - Indicate the number of deaths caused by the outbreak-causing disease during the outbreak. No. Encephalitis - Indicate the number of cases diagnosed with encephalitis during the outbreak. No. Hospitalized - Indicate the number of cases hospitalized due to measles or rubella during the outbreak. Lab Detail - 4 information cells No. Suspected cases with specimen - Indicate the number of suspected cases from whom specimens were collected for laboratory diagnostic procedures (detection of anti rubella or measles IgM). According to WHO Guidelines for elimination of measles, rubella and CRS, we expect that cases from the beginning of investigation (when cluster of cases is recognized) will be tested for both diseases (IgM for measles and IgM for rubella). Later, when the outbreak is confirmed by IgM results, countries with low incidence of both diseases should continue with testing of suspected case s for measles and rubella for DDg , regardless which disease is actually the cause of the outbreak. No. Lab conf. measles cases - Indicate the number of measles cases that are confirmed IgM positive. No. Lab conf. rubella cases - Indicate the number of rubella cases that are confirmed IgM positive. Genotype - Indicate the genotype of virus (with isolation or by PCR only), if performed. Only rubella cases - 2 information cells; to fill in for a rubella outbreak investigation AND for cases that are lab - confirmed rubella cases in measles outbreak investigation. No. Pregnant Women - Indicate the number of suspected rubella cases in pregnant women during the rubella outbreak OR indicate the number of confirmed rubella cases in pregnant women during the measles outbreak. No. WCBA - Indicate the number of suspected rubella cases in Women of Childbearing Age during the rubella outbreak OR indicate the number of confirmed rubella cases in Women of Childbearing Age during the measles outbreak. Name and contact detail of the person reporting this outbreak - Enter the contact information of the person that the WHO Regional Office can contact if there is a need for additional information. Date of this report to WHO Europe - Indicate the date when this report was sent to the WHO Regional Office for Europe . . Table "Epidemiological detail of confirmed cases (lab confirmed, epi linked and final clinical)" Enter information about confirmed cases during the outbreak regarding their age and immunization status. This information should be only for the diseases causing the outbreak and the related immunization status (for example, not rubella lab - confirmed cases during a measles outbreak or rubella immunization status of measles cases). The totals for rows and columns will be automatically calculated. Description of outbreak - Indicate the main epidemiological findings: any specificity regarding characteristics of affected institutions and communities, special populations, professional exposure, immunization status, age of cases, dominating diagnoses for hospitalization, high number of cases with sever e form of disease or other epidemiologically important findings. Measures taken to prevent/control further spread of outbreak - Indicate the main measures taken to prevent/control further spread of the outbreak, the outbreak response measures (e.g., school immunization). If it is possible, in the final closing outbreak report form indicate the risk management measures and long - term measures that are based on the lessons learned during this outbreak. Sub-national outbreak spread detail (please provide this detail if available) - In the case that epidemiological and laboratory findings are able to link other measles or rubella outbreaks or clusters in other administrative territories of the country, please enter information following the title row of the table. According to the national regulations, these cases can be considered as clusters of the reported outbreak or as individual outbreaks. If they are considered as separate outbreak(s), please enter this information in the “Comments” row and fill in an additional form for that outbreak(s). Technical report on implementation of supplementary immunization activities 1. Country: FORMTEXT 2. Dates of SIAs: FORMTEXT 3. Target provinces (if not a nationwide activity): FORMTEXT 4. Targets and results for measles / measles-rubella vaccine by first subnational level (state / province / region) Measles / Measles-Rubella /Measles-Mumps-Rubella Vaccine Area Target Age Target Pop No. Reached Admin Coverage Number (and % districts) > 95% coverage Survey Coverage (if available) Wastage Rate No. serious AEFI Serious AEFI attributed to SIA FORMTEXT FORMTEXT FORMTEXT FORMTEXT FORMTEXT FORMTEXT FORMTEXT FORMTEXT FORMTEXT FORMTEXT FORMTEXT FORMTEXT FORMTEXT FORMTEXT FORMTEXT FORMTEXT FORMTEXT FORMTEXT FORMTEXT FORMTEXT FORMTEXT FORMTEXT FORMTEXT FORMTEXT FORMTEXT FORMTEXT FORMTEXT FORMTEXT FORMTEXT FORMTEXT 5. Targets and results for other interventions by first subnational level (state / province / region) FORMTEXT < intervention name >* Area Target Age Target Pop No. Reached Admin Coverage Number (and % districts) > 95% coverage Survey Coverage FORMTEXT FORMTEXT FORMTEXT FORMTEXT FORMTEXT FORMTEXT FORMTEXT FORMTEXT FORMTEXT FORMTEXT FORMTEXT FORMTEXT FORMTEXT FORMTEXT FORMTEXT FORMTEXT FORMTEXT FORMTEXT FORMTEXT FORMTEXT FORMTEXT *Please fill out the above table for every intervention added to the SIA 6. Number (numerator and denominator) and % of monitored sites with more than 10% un-reached children during end-process monitoring or if LQAS is done, number and % of rejected lots. FORMTEXT Annex 1 : WHO guiding documents and examples Definitions Based on : Surveillance Guidelines for Measles, Rubella and Congenital Rubella Syndrome in the WHO European Region - Update December 2012 http://www.euro.who.int/__data/assets/pdf_file/0018/79020/e93035-2013.pdf?ua=1 and Eliminating measles and rubella. Framework for the verification process in the WHO European Region http://www.euro.who.int/__data/assets/pdf_file/0009/247356/Eliminating-measles-and-rubella-Framework-for-the-verification-process-in-the-WHO-European-Region.pdf?ua=1 Disease elimination: the absence of endemic measles or rubella cases in a defined geographical area for a period of at least 12 months, in the presence of a well-performing surveillance system. Verification of regional elimination : Regional elimination can be declared after 36 or more months of the absence of endemic measles or rubella in all Member States. Disease eradication: worldwide interruption of measles or rubella transmission in the presence of a verified, well-performing surveillance system. Endemic transmission : continuous transmission of indigenous or imported measles or rubella virus that persists for a period of 12 months or more in a defined geographical area. Re-establishment of endemic transmission: a situation in which epidemiological and laboratory evidence indicate the presence of a chain of transmission of a measles or rubella virus variant that continues uninterrupted for a period of 12 months or more in a defined geographical area where disease was previously eliminated. Outbreak or chain of transmission : 2 or more measles or rubella cases which are temporarily related and epidemiologically or virologically linked, or both. Classification of cases: Suspected measles case : a case with signs and symptoms consistent with measles clinical criteria: fever and maculopapular rash and cough or coryza (runny nose) or conjunctivitis (red eyes). Suspected rubella case: a case with signs and symptoms consistent with rubella clinical criteria: maculopapular rash and cervical, suboccipital or post-auricular adenopathy, or arthralgia/arthritis. Note : According to “Framework for verifying elimination of measles and rubella”, Weekly epidemiological record, No. 9, 2013, 88, 89–100 ( http://www.who.int/wer/2013/wer8809.pdf?ua=1 ) Suspected case of measles or rubella – A patient in whom a health-care worker suspects measles or rubella infection, or a patient with fever and maculopapular (non-vesicular) rash Laboratory-confirmed measles case: a suspected case that meets the laboratory criteria for measles case confirmation. Laboratory-confirmed rubella case: a suspected case that meets the laboratory criteria for rubella surveillance case confirmation. Epidemiologically linked measles case: a suspected case that has not been adequately tested by laboratory and that was in contact with a laboratory-confirmed measles case 7–18 days before the onset of rash. Epidemiologically linked rubella case: a suspected case that has not been adequately tested by laboratory and that was in contact with a laboratory-confirmed rubella case 12–23 days prior to onset of the disease. Clinically compatible measles case: a suspected case that has not been adequately tested by laboratory and has not been epidemiologically linked to a confirmed measles case. Clinically compatible rubella case: a suspected case that has not been adequately tested by laboratory and has not been epidemiologically linked to a confirmed rubella case. Endemic case: a laboratory-confirmed or epidemiologically linked case of measles or rubella resulting from endemic transmission of measles or rubella virus. Imported case: a case exposed outside the country during the 7-18 days (measles) or 12-23 days (rubella) prior to rash onset as supported by epidemiological and/or virological evidence. Import-related case: a locally-acquired measles or rubella infection occurring as part of a chain of transmission originating in an imported case, as supported by epidemiological and/or virological evidence. (Note: if transmission of import-related cases persists for 12 months or more, cases are no longer considered as import-related but as endemic). Discarded case : a suspected case that was investigated and discarded, either through negative results of adequate laboratory testing for measles and rubella or by an epidemiological link to a laboratory-confirmed case of another disease; in addition, IgM-positive cases in recent vaccine recipients can be discarded if they meet all of the following criteria: history of vaccination with relevant vaccine 7 days to 6 weeks prior to specimen collection; onset of rash 7−14 days after vaccination; no evidence of virus transmission revealed by active search in community; no history of travel to areas in which the virus is known to be circulating. Genotype: Operational taxonomic unit defined on the basis of nucleotide variation between viral strains. Measles virus genotypes are defined on the genetic analysis of the N-450 sequence, which is the most variable region of the measles virus genome. Rubella virus genotypes are defined on genetic analysis of the E1- 739 sequence. Named strain (measles only): Measles virus variant specifically identified in MeaNS as a representative N-450 sequence due to its important prevalence within the database (usually associated with widespread transmission). It allows describing viral diversity with finer resolution within a single genotype. Case classification algorithm for measles and rubella 1 . 2 Description of “Indicators and targets” for measuring performance of measles and rubella surveillance Indicator Description Target and Notes Timeliness of reporting (to national level) (T) Percentage of measles or rubella routine surveillance reports a submitted to the national level by the deadline b Target: ≥80% Example: A Number of reports submitted by the deadline B Number of expected reports T=(A*100)/B (%) Completeness of reporting (to national level) (C) Percentage of measles or rubella routine surveillance reports a submitted to the national level Target: ≥80% Example: E Number of submitted reports B Number of expected reports C=(E*100)/B (%) Rate of laboratory investigations (L) Percentage of cases suspected for measles or rubella with adequate specimens c collected and tested in a WHO accredited or proficient laboratory d Note: Exclude from the denominator any suspected cases not tested by a laboratory and (a) confirmed by epidemiological linkage, or (b) discarded as non-measles/non-rubella by epidemiological linkage to a laboratory-confirmed case of another communicable disease or epidemiological linkage to a measles or rubella IgM - negative case Target: ≥80% Example: F Number of suspected measles or rubella cases with ad equate specimens collected and tested in a proficient laboratory G Number of suspected cases L=(F*100)/G (%) Rate of discarded cases (D) The rate of suspected measles or rubella cases investigated and discarded as non-measles or non-rubella cases using laboratory testing in a proficient laboratory and/or epidemiological linkage to another confirmed disease Target: At least 2 discarded measles or rubella cases per 100 000 Example: H Number of suspected measles or rubella cases investigated and discarded as non- measles or non-rubella cases J Population D=(H*100 000)/J Representativeness of reporting discarded cases (R) Percentage of subnational administrative territories (e.g. at the province level or its administrative equivalent) reporting the rate of discarded cases (D) at least 2 per 100 000 population per year Target: ≥80% Example: K Number of subnational administrative territories reporting the rate of discarded cases (D) at least 2 per 100 000 population per year M Number of subnational administrative territories R=(K*100)/M (%) Viral detection (V) Percentage of laboratory-confirmed chains of transmission of measles or rubella with samples adequate for viral detection collected and tested in an accredited laboratory e Target: ≥ 80% Example: P Number of chains of transmission of measles or rubella for which adequate samples have been submitted for viral detection / genotyping Q Number of chains of transmission identified V=(P*100)/Q (%) Origin of infection identified (O) Percentage of measles or rubella cases for which the origin of infection (e.g. imported, import-related or endemic) has been identified Target: ≥ 80% Example: W Number of measles or rubella cases for which the origin of infection (e.g. imported, import-related or endemic) has been identified X The total number of measles or rubella cases O=(W*100)/X (%) Timeliness of investigation (I) Percentage of suspected measles or rubella cases with an adequate investigation f initiated within 48 hours of notification Target: ≥ 80% Example: Y Number of measles or rubella cases with an adequate investigation Z Number of suspected measles or rubella cases, respectively I=(Y*100)/Z (%) a Regular monthly or weekly reports, including “zero” reports to be submitted by each surveillance reporting unit to national level. This does not refer to lab reporting of cases. b The deadline to submit data on the previous months or week to be defined by Member State c A single clinical sample obtained at the first contact with the health-care system at any time within 28 days after rash onset is considered adequate for surveillance purposes . d Llaboratory that is WHO accredited and/or has an established quality assurance programme with oversight by a WHO accredited laboratory . e M e asles a n d r u b e lla vi r u s es c a n b e de t e c t e d in nasal se c r eti o n s, urin e , s e r um a n d w h ol e b l oo d , a n d d r y b l oo d s p o t s u p t o se v e n d a y s a f t e r o n s e t o f t h e ras h a n d i n o r a l f l uid fo r e v en l o n g e r . f An adequate investigation includes the collection of at least the following essential data elements from each suspected measles/rubella case: case identifier, age (or date of birth), date of rash onset, date of specimen collection and vaccination status. Countries may wish to collect other data that may be important for epidemiologic investigation Alternative indicators The following two indicators should be used by countries that are unable to report standard indicators on timeliness of reporting and/or rate of discarded cases as described above. Timeliness of notification (Tn) Alternative to Timeliness and Completeness of reporting Percentage of measles or rubella case-based reports to surveillance system submitted within 48 hours of the rash onset Target: ≥80% Example: Number of reports submitted within 48 hours Number of suspected cases Tn=(A*100)/B (%) Rate of cases tested negativ e for measles or rubella IgM (N ) Alternative to Rate of discarded cases The rate of cases of measles or rubella-like illnesses (MLI/RLI) whose specimens tested IgM nega tive in a proficient laboratory Target: At least 2 MLI/RLI cases tested negative per 100 000 population (nationwide) Example: Number of measles or rubella cases tested negative for measles or rubella IgM Population N=(A*100 000)/B 1 . 3 Sustai nin g measles and rubella elimination after verification - Discussion points on risk of re-establishing endemic transmission of diseases C ountries verified by the RVC as having achiev ed interruption of endemic measles and rubella transmission for a period of 36 months should assess their risks for re-establishing endemic transmission of diseases. Recognizing that the risk of importation will exist as long as measles and rubella viruses are present and circulating in other countries, each national public health system’s priorities are high immunity of the population, sensitive surveillance system and established conditions and capacities for prompt and comprehensive outbreak response. Below is a list of possible challenges and suggestions for sustaining elimination status , developed based on recognized and reported situations in countries. It is not a comprehensive list of all issues and it is not intended to be used as a tool with measurable indicators or thresholds . W e expect that t he National Verification Committee and national technical staff ( the NVC’s Secretariat) will use it to review whether these challenges are present in the country ; whether they are recognized and being addressed, or whether there is a plan to address them ; and what role the NVC can play or is playing in supporting the national public health system dealing with these issues , with expected technical inputs from and involvement of the national technical advisory bodies and structures. Immunity/susceptibility of population National immunization programme performance in recent years and routine i mmunization coverage Monitor rates and trends related to coverage , timelines of immunization (according to age-specific recommendation s ), and potential variation in coverage per vaccine dose ( due to implementation, availability, acceptance or other reasons ) with first and/or second dose. Define the most affected by suboptimal coverage or downward trends (e.g. territories, populations, minorities/ethnic groups, social-economic groups …) . Clarify the main reasons for this situation, list ongoing and planned activities to deal with this situation and discuss further and additional steps (benefits of intervention in policy segment, influencing decision - makers, or addressing the public) to reach/ keep coverage at 95% or higher with both doses . Susceptible population among adolescents and adults Review a vailab le d ata or estimat e the size of the susceptible population among adolescent and adults (not immunized or immunized with just one dose due to absence of immunization programme, different requirements and schedule , gaps in vaccine supply) and any supplemental immunization activity taken or planned (army service, university entry requirements, for specific occupations or work in health and educational system, for international travel etc.) Review p ossibility of aggregation of susceptibles or possible increased contacts among susceptibles due to social or family relations (economic migration, education institutions, family of susceptible adults and newborn, parents and children contacts in kindergartens ). Review i nternal (inside country) migration, and moving of susceptibles (countries with historical difference in immunization programme for different territories, or with different coverage at different subnational territories). Identify the p roportion of adolescents and adults who are born in other countries and who were immunized according to immunization programme s of th ose countr ies , and review their immunization programmes ( coverage may be higher or lower, immunization and two-dose schedule introduced earlier or later than in your country) . Specific subgroups of population with low immunization coverage or that are not immunized Identify a ll such groups and the reasons for their low immunization coverage (access, denial, refusal, poor services) . Have adequate steps and strategies to address their needs been taken , or planed ? If needed, plan additional activities to better define these groups and the best approach to increase their coverage . Surveillance High sensitivity of health care system/health care workers to measles/rubella/CRS in absence of diseases Check whether h ealth care workers ( HCW ) are trained and systematically reminded to stay vigilant and suspect measles/rubella/CRS, through diseases-specific reporting, or syndromic surveillance, or as part of programmes for surveillance and reporting of congenital malformation. If some challenges are recognized, check whether specific action s are conducted and plan n ed, and if not , plan for actions to be discussed. Adequate quality of surveillance Assess r eliability and adequacy of diseases surveillance against global measles and rubella surveillance indicators . If global surveillance indicators are not implementable or are incompatible with the current health system structure and procedures, other indicators should be considered in order to assess quality of surveillance. A high quality surveillance is the one that have every suspected case of measles, rubella and CRS (appearing anywhere in the country during the year ) reported, investigated and confirm or discard . Ensure that a ll segments of surveillance (clinical, epidemiological and laboratory) are coordinated and cooperate , and that every suspected case is investigated adequately and timely to identify details of genotype and lineages of the viruses. Ensure that s urveillance data are systematically used and analy s ed to detect and define susceptible individuals and groups , and that adequate measures to immunize them are taken/planned . Outbreak response Ensure that l essons learn ed from previous outbreaks are /will be used to improve outbreak response . Check that a ll stakeholders understand that an outbreak is an emergency and its control is a high priority . Check that a ll requirements for adequate, timely response are in place , including l egislation allo wing timely intervention ; up to date technical guidelines and protocols ; health care workers and all other critical participants in outbreak response are trained and aware of their role and responsibility ; s ufficient resources (financial, human , vaccine, logistics) are or can quickly become available in short period , prepared and trained a dvocacy and communication teams who have developed materials, messages and tailored ways of communication (different for different target population s ) ; planned and prepared c ooperation with partners (governmental sectors, private sector, NGOs, donors, media) . Use o utbreak analysis systematically to define susceptible s , and undertake adequate measures to immunize them to prevent similar events in future .
WORLD HEALTH ORGANIZATION
ORGANISATION MONDIALE DE LA SANTÉ
WELTGESUNDHEITSORGANISATION Date: 31 January 2020
ВСЕМИРНАЯ ОРГАНИЗАЦИЯ ЗДРАВООХРАНЕНИЯ
REGIONAL OFFICE FOR EUROPE Ms Elen Ohov
BUREAU RÉGIONAL DE L’EUROPE
REGIONALBÜRO FÜR EUROPA
Adviser
ЕВРОПЕЙСКОЕ РЕГИОНАЛЬНОЕ БЮРО European Union Affairs and International Co-
Head office:
operation Department
UN City, Marmorvej 51, Ministry of Social Affairs
DK-2100 Copenhagen Ø, Denmark Suur-Ameerika 1
Tel.: +45 45 33 70 00; Fax: +45 45 33 70 01
Email:
[email protected] 10122 Tallinn
Website: http://www.euro.who.int Estonia
Our reference: Your reference:
Notre référence: Votre référence:
Unser Zeichen: Ihr Zeichen:
См. наш номер: На Ваш номер:
Dear Ms Ohov,
Annual status update (ASU) on measles and rubella elimination – 2019
The Vaccine-preventable Diseases and Immunization programme (VPI) of the WHO Regional Office for
Europe is pleased to inform you that the ninth meeting of the European Regional Verification Commission for
Measles and Rubella Elimination (RVC) will be held in June 2020, to review status and achievements towards
measles and rubella elimination in countries and in the Region. The RVC will base its decision on the status of
measles and rubella elimination in each Member State and the Region on reports submitted by the respective
national verification committees (NVCs).
All Member States are requested to submit their ASU on measles and rubella elimination activities for the year
2019 with all relevant information no later than 15 April 2020. Adhering to this deadline is essential to ensure
sufficient time for the analysis of data before the RVC meets. An ASU template for 2019 and all additional
documents, prepared and approved by the respective NVC, should be uploaded to SharePoint or submitted via
e-mail (
[email protected]) to the WHO Regional Office for Europe (RVC Secretariat). We kindly ask you to use
the credentials and instructions for using SharePoint as previously provided.
Attached you will find a template for the 2019 ASU. To ensure consistency, please follow the proposed format
as explained in the instructions. To facilitate your work on preparation of the ASU 2019, please use an Excel
file and its pre-prepared tables with formulas that will help you in calculating data. A few extra worksheets are
developed to facilitate analysis of data at subnational level and to allow presenting detailed molecular
epidemiology information if available, for your convenience. We recommend to submit this file together with
ASU 2019.
In addition, we encourage you to submit any additional information that will assist the RVC in determining the
status of measles and rubella elimination in your country. Additional information that does not fit in the
template may be uploaded as a separate document. VPI stands ready to support you in ensuring timely
completion of the ASU.
We would like to take this opportunity to re-emphasize the importance of ensuring that data submitted in this
annual update are accurate and consistent with other national reports submitted to the Regional Office.
We would also like to stress that all reports and additional information received from the NVCs during the
verification process will be carefully reviewed and analysed. RVC conclusions based on this information will
be publicly presented in various forms, as part of planned communication activities to recognize Member
States’ efforts and progress towards the Region’s immunization goals.
UN City, Marmorvej 51 Tel.: +45 45 33 70 00 Email:
[email protected]
DK-2100 Copenhagen Ø Fax: +45 45 33 70 01 Website: http://www.euro.who.int
Denmark
Should you have any questions regarding the provided template and uploading of documents, please contact Dr
Dragan Jankovic (
[email protected]), Dr Zhanara Bekenova (
[email protected]) and Ms Malika
Abdusalyamova (
[email protected]).
We would like to stress that your efforts in documenting the absence of endemic transmission in your country
are highly appreciated and critical to achieving measles and rubella elimination in the Region.
The RVC and Secretariat are committed to providing you with any support that you may require.
Sincerely yours,
Dr Siddhartha Datta
Programme Manager
Vaccine-preventable Diseases
and Immunization
Copy for information to:
Ms Triin Uusberg, Head, European and International Coordination Department, Ministry of Social Affairs,
Suur-Ameerika 1, 10129 Tallinn, Estonia
H.E. Ms Katrin Saarsalu-Layachi, Ambassador Extraordinary and Plenipotentiary, Permanent Representative,
Permanent Mission of the Republic of Estonia to the United Nations Office and other international
organizations in Geneva, Chemin du Petit-Saconnex 28A, CH-1209 Genève, Switzerland
H.E. Mr William Mart Laanemäe, Ambassador Extraordinary and Plenipotentiary, agréé, Embassy of the
Republic of Estonia, Frederiksgade 19, 4th floor, 1265 Copenhagen K, Denmark
Ms Marge Reinap, Head of WHO Office, WHO Country Office, Estonia, Paldiski Road 81, 10617 Tallinn,
Estonia
–2–
Saatja: ABDUSALYAMOVA, Malika <
[email protected]>
Saadetud: 03.02.2020 14:45
Adressaat: Elen Ohov <
[email protected]>
Koopia: WHO Europe RVC <
[email protected]>; Triin Uusberg
<
[email protected]>; SM Info <
[email protected]>; <
[email protected]>;
<
[email protected]>; REINAP, Marge <
[email protected]>; BEKENOVA,
Zhanara <
[email protected]>
Teema: MR ASU 2019
Please see the attached correspondence sent from the World Health
Organization, Regional Office for Europe. One or more attachments may be
included.Veuillez vous r¨¦f¨¦rer ¨¤ la correspondance ci-jointe du Bureau
r¨¦gional de l'Europe de l'Organisation mondiale de la sant¨¦. Une ou
plusieurs annexes peuvent ¨ºtre jointes.Mit der Bitte um Kenntnisnahme
der beiliegenden Korrespondenz (eine oder mehrere Anlagen),
Weltgesundheitsorganisation, Regionalb¨¹ro f¨¹r Europa.§³§Þ.
§á§â§Ú§Ü§â§Ö§á§Ý§Ö§ß§ß§í§Ö §á§Ú§ã§î§Þ§Ñ §à§ä §¦§Ó§â§à§á§Ö§Û§ã§Ü§à§Ô§à
§â§Ö§Ô§Ú§à§ß§Ñ§Ý§î§ß§à§Ô§à §Ò§ð§â§à §£§ã§Ö§Þ§Ú§â§ß§à§Û
§à§â§Ô§Ñ§ß§Ú§Ù§Ñ§è§Ú§Ú §Ù§Õ§â§Ñ§Ó§à§à§ç§â§Ñ§ß§Ö§ß§Ú§ñ (§à§Õ§Ú§ß §Ú§Ý§Ú
§ß§Ö§ã§Ü§à§Ý§î§Ü§à §á§â§Ú§Ü§â§Ö§á§Ý§Ö§ß§ß§í§ç §æ§Ñ§Û§Ý§à§Ó).